Patient Dosing & Self-Administration Information

While there are guidelines on how to begin Hizentra therapy, the dosage should be individualized based on the patient's clinical response to therapy and serum immunoglobulin G (IgG) trough levels.

For weekly dosing, start Hizentra treatment 1 week after the last IVIg treatment. For biweekly (every 2 weeks) dosing, start treatment 1-2 weeks after the last IVIg infusion or 1 week after the last weekly SCIg infusion. The initial weekly dose of Hizentra is calculated by converting the IVIg dose into a weekly equivalent and then apply a dose adjustment factor of 1.53. When switching to biweekly (every 2 weeks) dosing, multiply the calculated Hizentra weekly dose by 2. The goal is to achieve a systemic serum IgG exposure not inferior to that of the previous IVIg treatment (if applicable).

To calculate the recommended starting dose, use this formula:

Initial recommended dose of Hizentra
= 1.53 x
Previous IVIg dose(grams)
Number of weeks between scheduled IVIg doses

Try the Hizentra Dosage Calculator

The Hizentra dosage calculator can save you time when determining the recommended dose of Hizentra for your patients.

Over time, the dose may have to be adjusted to achieve the desired results. To determine if a dose adjustment is needed, measure the patient's serum IgG through level 2 to 3 months after transitioning to Hizentra. To learn how to adjust the dose, please see the full Prescribing Information.

Guide for Administering Self-Infused Subcutaneous Ig (SCIg) Therapy

Hizentra should be administered subcutaneously only. Do not administer intravenously. Hizentra can be dosed either weekly or biweekly (every 2 weeks), using an infusion pump and small needle(s).

  • For weekly dosing use up to 4 sites simultaneously or up to 12 sites consecutively per infusion. For biweekly dosing increase the number of injection sites as needed.
  • Recommended infusion sites include the stomach, thighs, upper arms, or hips
  • SC needles are smaller than IV needles. Depending on a patient’s size and weight, a needle as short as 4 mm or as long as 14 mm can be used
  • Infusion should not exceed 25 mL/hour per site
Subcutaneous Infusion Sites

Hear Carla Duff, ARNP Discuss Self-Administration With her Patients

Professionals Using Hizentra Dosing & Administration
Expand

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

WARNING:THROMBOSIS

Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. See full prescribing information for complete boxed warning.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Monitor patients for aseptic meningitis syndrome (AMS), which has been reported with SCIg. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. Also monitor patients for clinical signs of hemolysis or transfusion-related acute lung injury (TRALI).

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritus, vomiting, upper abdominal pain, migraine and pain.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra including boxed warning.

Collapse
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2014 CSL Behring. The product information presented on this site is intended for US residents only. HIZ14-01-0001 3/2014